Payment overview · 2025
General Payments
$316.48
22 reported records · 9 companies
Healthcare provider profile · identity verified
Melanie Dawn Davis
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GRAY, TN · NPI 1972893139
Verified facts
What the public records show
CMS Open Payments records show Melanie Dawn Davis received $316.48 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.43 | 51.0% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.00 | 10.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.56 | 7.4% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.48 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.67 | 5.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.48 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.14 | 5.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.54 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.18 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.48 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.44 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $117.58 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.99 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.56 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 213 | 63 |
| Omeprazole | Omeprazole | 208 | 59 |
| Losartan Potassium | Losartan Potassium | 199 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 59 |
| Gabapentin | Gabapentin | 175 | 38 |
| Lisinopril | Lisinopril | 171 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 166 | 50 |
| Trazodone Hcl | Trazodone Hcl | 134 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 34 |
| Montelukast Sodium | Montelukast Sodium | 115 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 31 |
| Alprazolam | Alprazolam | 103 | 17 |
| Meloxicam | Meloxicam | 99 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 35 |
| Buspirone Hcl | Buspirone Hcl | 96 | 24 |
| Metformin Hcl | Metformin Hcl | 80 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 23 |
| Famotidine | Famotidine | 75 | 24 |
| Ezetimibe | Ezetimibe | 72 | 23 |
| Furosemide | Furosemide | 69 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 13 |
| Alendronate Sodium | Alendronate Sodium | 60 | 18 |
| Simvastatin | Simvastatin | 57 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 12 |
| Prednisone | Prednisone | 56 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 48 |
| Metformin Hcl Er | Metformin Hcl | 53 | 15 |
| Bupropion Xl | Bupropion Hcl | 51 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | suppressed |
| Eliquis | Apixaban | 50 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 16 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Baclofen | Baclofen | 46 | 15 |
| Jardiance | Empagliflozin | 46 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 29 |
| Azithromycin | Azithromycin | 42 | 30 |
| Ozempic | Semaglutide | 42 | 13 |
| Potassium Chloride | Potassium Chloride | 42 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Methocarbamol | Methocarbamol | 39 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Acyclovir | Acyclovir | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 15 |
| Fluconazole | Fluconazole | 37 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 12 |
| Cephalexin | Cephalexin | 32 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Spironolactone | Spironolactone | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 12 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Nystatin | Nystatin | 26 | 12 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Desloratadine | Desloratadine | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Mupirocin | Mupirocin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.48 · 22 records | Novo Nordisk Inc | AREXVY, CAPVAXIVE, GARDASIL 9, GVOKE HYPOPEN, Heplisav-B, Kerendia, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error